Citadel Advisors
EBS icon

Citadel Advisors’s Emergent Biosolutions EBS Stock Holding History

Citadel Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-232,019
Closed -$2.4M – 13243
2025
Q4 		$2.87M Sell
232,019
-107,632
-32% -$1.15M ﹤0.01% 5255
2025
Q3 		$3M Buy
339,651
+58,150
+21% +$452K ﹤0.01% 5314
2025
Q2 		$1.8M Sell
281,501
-13,415
-5% -$76.8K ﹤0.01% 5908
2025
Q1 		$1.43M Buy
294,916
+144,090
+96% +$1.19M ﹤0.01% 6178
2024
Q4 		$1.44M Buy
150,826
+130,338
+636% +$1.2M ﹤0.01% 6304
2024
Q3 		$171K Sell
20,488
-325,866
-94% -$2.96M ﹤0.01% 10382
2024
Q2 		$2.36M Buy
346,354
+263,284
+317% +$1.13M ﹤0.01% 5011
2024
Q1 		$210K Buy
83,070
+8,176
+11% +$18.4K ﹤0.01% 10216
2023
Q4 		$180K Sell
74,894
-1,125,649
-94% -$2.65M ﹤0.01% 10103
2023
Q3 		$4.08M Buy
1,200,543
+579,140
+93% +$3.21M ﹤0.01% 3979
2023
Q2 		$4.57M Buy
621,403
+183,944
+42% +$1.71M ﹤0.01% 3781
2023
Q1 		$4.53M Buy
437,459
+244,353
+127% +$2.95M ﹤0.01% 3980
2022
Q4 		$2.28M Sell
193,106
-383,378
-67% -$5.93M ﹤0.01% 5229
2022
Q3 		$12.1M Buy
576,484
+417,773
+263% +$11.6M ﹤0.01% 2484
2022
Q2 		$4.93M Buy
158,711
+20,937
+15% +$715K ﹤0.01% 3817
2022
Q1 		$5.66M Buy
137,774
+83,303
+153% +$3.67M ﹤0.01% 3932
2021
Q4 		$2.37M Sell
54,471
-178,007
-77% -$8.05M ﹤0.01% 5855
2021
Q3 		$11.6M Buy
232,478
+90,716
+64% +$5.49M ﹤0.01% 2814
2021
Q2 		$8.93M Buy
141,762
+40,671
+40% +$2.61M ﹤0.01% 3264
2021
Q1 		$9.39M Buy
101,091
+11,116
+12% +$1.14M ﹤0.01% 3058
2020
Q4 		$8.06M Buy
89,975
+45,734
+103% +$4.2M ﹤0.01% 2930
2020
Q3 		$4.57M Buy
44,241
+41,395
+1,454% +$4.46M ﹤0.01% 3290
2020
Q2 		$225K Sell
2,846
-132,129
-98% -$9.85M ﹤0.01% 8355
2020
Q1 		$7.81M Sell
134,975
-13,015
-9% -$750K ﹤0.01% 2144
2019
Q4 		$7.98M Buy
147,990
+98,727
+200% +$5.35M ﹤0.01% 2472
2019
Q3 		$2.58M Sell
49,263
-41,686
-46% -$1.94M ﹤0.01% 4095
2019
Q2 		$4.39M Sell
90,949
-12,858
-12% -$616K ﹤0.01% 3293
2019
Q1 		$5.25M Buy
103,807
+60,292
+139% +$3.56M ﹤0.01% 2936
2018
Q4 		$2.58M Sell
43,515
-45,367
-51% -$2.92M ﹤0.01% 3758
2018
Q3 		$5.85M Buy
88,882
+53,849
+154% +$3.14M ﹤0.01% 2787
2018
Q2 		$1.77M Buy
35,033
+18,969
+118% +$988K ﹤0.01% 4295
2018
Q1 		$846K Buy
16,064
+5,338
+50% +$266K ﹤0.01% 5055
2017
Q4 		$498K Sell
10,726
-6,251
-37% -$263K ﹤0.01% 5646
2017
Q3 		$687K Sell
16,977
-120,747
-88% -$4.37M ﹤0.01% 4867
2017
Q2 		$4.67M Buy
137,724
+28,963
+27% +$894K ﹤0.01% 2193
2017
Q1 		$3.16M Buy
108,761
+32,906
+43% +$1M ﹤0.01% 2524
2016
Q4 		$2.49M Buy
75,855
+11,473
+18% +$344K ﹤0.01% 2696
2016
Q3 		$2.03M Buy
64,382
+49,493
+332% +$1.44M ﹤0.01% 2952
2016
Q2 		$419K Sell
14,889
-120,927
-89% -$4.74M ﹤0.01% 4738
2016
Q1 		$4.94M Buy
135,816
+132,467
+3,955% +$4.68M 0.01% 1792
2015
Q4 		$134K Sell
3,349
-15,263
-82% -$532K ﹤0.01% 6351
2015
Q3 		$530K Buy
18,612
+941
+5% +$31K ﹤0.01% 4730
2015
Q2 		$583K Sell
17,671
-107,557
-86% -$3.33M ﹤0.01% 4725
2015
Q1 		$3.6M Buy
125,228
+56,312
+82% +$1.62M ﹤0.01% 2388
2014
Q4 		$1.88M Sell
68,916
-56,312
-45% -$1.34M ﹤0.01% 2985
2014
Q3 		$2.67M Buy
125,228
+113,848
+1,000% +$2.61M ﹤0.01% 2562
2014
Q2 		$256K Sell
11,380
-84,282
-88% -$1.96M ﹤0.01% 5267
2014
Q1 		$2.42M Buy
95,662
+46,836
+96% +$1.18M ﹤0.01% 2463
2013
Q4 		$1.12M Sell
48,826
-6,274
-11% -$131K ﹤0.01% 3116
2013
Q3 		$1.05M Sell
55,100
-39,109
-42% -$698K ﹤0.01% 3059
2013
Q2 		$1.36M Buy
+94,209
New +$1.36M ﹤0.01% 2871

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's EBS Position: Q1 2026 in Review

Citadel Advisors sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 232,019 shares — an estimated $2.4M sold.

Citadel Advisors first reported a position in EBS in Q2 2013 and held it in 51 quarters. The position peaked at $12.1M in Q3 2022. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Citadel Advisors reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 232,019 Emergent Biosolutions shares in Q1 2026, an estimated $2.4M.
  • Citadel Advisors first reported a position in Emergent Biosolutions in Q2 2013 and held it in 51 quarters.
  • Citadel Advisors's Emergent Biosolutions position peaked at $12.1M in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.